BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 26926424)

  • 21. p53 ubiquitination: Mdm2 and beyond.
    Brooks CL; Gu W
    Mol Cell; 2006 Feb; 21(3):307-15. PubMed ID: 16455486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual-site regulation of MDM2 E3-ubiquitin ligase activity.
    Wallace M; Worrall E; Pettersson S; Hupp TR; Ball KL
    Mol Cell; 2006 Jul; 23(2):251-63. PubMed ID: 16857591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mdm2 RING mutation enhances p53 transcriptional activity and p53-p300 interaction.
    Clegg HV; Itahana Y; Itahana K; Ramalingam S; Zhang Y
    PLoS One; 2012; 7(5):e38212. PubMed ID: 22666487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MSL2 promotes Mdm2-independent cytoplasmic localization of p53.
    Kruse JP; Gu W
    J Biol Chem; 2009 Jan; 284(5):3250-3263. PubMed ID: 19033443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice.
    Jung CR; Lim JH; Choi Y; Kim DG; Kang KJ; Noh SM; Im DS
    J Clin Invest; 2010 Dec; 120(12):4493-506. PubMed ID: 21060154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutant p53 Sequestration of the MDM2 Acidic Domain Inhibits E3 Ligase Activity.
    Yang L; Song T; Cheng Q; Chen L; Chen J
    Mol Cell Biol; 2019 Feb; 39(4):. PubMed ID: 30455251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
    Ghosh M; Huang K; Berberich SJ
    Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of p53 level by UBE4B in breast cancer.
    Zhang Y; Lv Y; Zhang Y; Gao H
    PLoS One; 2014; 9(2):e90154. PubMed ID: 24587254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of p53 degradation.
    Chao CC
    Clin Chim Acta; 2015 Jan; 438():139-47. PubMed ID: 25172038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin receptor tyrosine kinase substrate enhances low levels of MDM2-mediated p53 ubiquitination.
    Wang KS; Chen G; Shen HL; Li TT; Chen F; Wang QW; Wang ZQ; Han ZG; Zhang X
    PLoS One; 2011; 6(8):e23571. PubMed ID: 21887275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of p53 and MDM2 activity by MTBP.
    Brady M; Vlatkovic N; Boyd MT
    Mol Cell Biol; 2005 Jan; 25(2):545-53. PubMed ID: 15632057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Critical contribution of the MDM2 acidic domain to p53 ubiquitination.
    Kawai H; Wiederschain D; Yuan ZM
    Mol Cell Biol; 2003 Jul; 23(14):4939-47. PubMed ID: 12832479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells.
    Duan W; Gao L; Wu X; Zhang Y; Otterson GA; Villalona-Calero MA
    Exp Cell Res; 2006 Oct; 312(17):3370-8. PubMed ID: 16934800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MDM2 E3 ligase activity is essential for p53 regulation and cell cycle integrity.
    Chinnam M; Xu C; Lama R; Zhang X; Cedeno CD; Wang Y; Stablewski AB; Goodrich DW; Wang X
    PLoS Genet; 2022 May; 18(5):e1010171. PubMed ID: 35588102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
    Honda R; Yasuda H
    EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unlocking the Mdm2-p53 loop: ubiquitin is the key.
    Clegg HV; Itahana K; Zhang Y
    Cell Cycle; 2008 Feb; 7(3):287-92. PubMed ID: 18235222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ribosomal protein S7 is both a regulator and a substrate of MDM2.
    Zhu Y; Poyurovsky MV; Li Y; Biderman L; Stahl J; Jacq X; Prives C
    Mol Cell; 2009 Aug; 35(3):316-26. PubMed ID: 19683495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay.
    Herman AG; Hayano M; Poyurovsky MV; Shimada K; Skouta R; Prives C; Stockwell BR
    Cancer Discov; 2011 Sep; 1(4):312-25. PubMed ID: 22586610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MDM2 protein-mediated ubiquitination of numb protein: identification of a second physiological substrate of MDM2 that employs a dual-site docking mechanism.
    Sczaniecka M; Gladstone K; Pettersson S; McLaren L; Huart AS; Wallace M
    J Biol Chem; 2012 Apr; 287(17):14052-68. PubMed ID: 22337874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of p53 degradation by Mdm2 acetylation.
    Wang X; Taplick J; Geva N; Oren M
    FEBS Lett; 2004 Mar; 561(1-3):195-201. PubMed ID: 15013777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.